h1-logo-main (1).png
H1 Launches H1 Mobile App to Empower Medical Affairs with Real-Time KOL Insights and Expertise on the Go
August 14, 2023 09:00 ET | H1
NEW YORK, Aug. 14, 2023 (GLOBE NEWSWIRE) -- H1, the leading source of truth for global HCP, clinical, scientific, and research information, today announced the release of the iOS mobile app, H1...
MNPR Triangle 2.JPG
Monopar Provides Encouraging Camsirubicin Clinical Data Update
August 08, 2023 07:00 ET | Monopar Therapeutics Inc.
WILMETTE, Ill., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for...
New Data at Heart Rhythm 2023 Suggests that Unipolar Signals May be Used for a More Precise, Accurate Approach to Treating Arrhythmias
May 19, 2023 07:30 ET | BioSig Technologies, Inc.
Data from three abstracts highlight the potential of an optimized radiofrequency ablation technique for pulmonary vein isolation (PVI) Preservation of raw unipolar signal using BioSig’s...
Arbutus Biopharma Logo
Arbutus Provides AB-729 Clinical Data and AB-161 Preclinical Data as Oral Presentations at the Global Hepatitis Summit 2023
April 27, 2023 03:20 ET | Arbutus Biopharma Corporation
Seven patients with cHBV remain off all treatment and continue to maintain low levels of HBV DNA and HBsAg for at least one and half years post- AB-729 treatment AB-161 provides robust anti-HBV...
Neurona Therapeutics Presents Updated Data from the NRTX-1001 Cell Therapy Trial in Adults with Drug-resistant Focal Epilepsy at American Academy of Neurology (AAN) 2023 Annual Meeting
April 24, 2023 08:00 ET | Neurona Therapeutics
NRTX-1001 administration is well-tolerated with continued seizure reduction of >90% in the first two patients at nine- and five-months post-treatment, respectively Impaired-awareness seizures...
Medigene AG presents final Phase I data of TCR-T cell therapy MDG1011 in patients with high-risk blood cancers
April 24, 2023 05:00 ET | Medigene AG
MDG1011 was generally well tolerated in nine heavily pre-treated patients across three ascending dose levelsNo neurotoxicity or dose-limiting toxicities observedTwo out of nine patients showed early...
h1-logo-main (1).png
H1.co Named 2023 Website of the Year by the Health And IT Marketing Community
April 18, 2023 09:00 ET | H1
NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) -- H1, the connecting force for global healthcare provider, clinical, science, and research information, is proud to announce that it has been awarded the...
MNPR Triangle 2.JPG
Monopar Announces Camsirubicin Clinical Program Update - Improved Side Effect Profile Seen to Date Compared to Doxorubicin
February 14, 2023 07:00 ET | Monopar Therapeutics Inc.
WILMETTE, Ill., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Spexis logo.png
Spexis reports solid safety and pharmacokinetics results from first-in-human study with inhaled murepavadin, a novel macrocycle compound
January 09, 2023 01:20 ET | Spexis AG
Ad hoc announcement pursuant to Art. 53 LR Inhaled murepavadin shown to be well tolerated at all dose levels Program derived from Spexis’ macrocycle platformData support moving forward...
Global Crypto Health Market
Crypto Health Market Research Report - Global Forecast to 2027 - Cumulative Impact of COVID-19
December 20, 2022 04:03 ET | Research and Markets
Dublin, Dec. 20, 2022 (GLOBE NEWSWIRE) -- The "Crypto Health Market Research Report by Function, End User, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to ...